Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. [PDF]
Cochrane Database Syst Rev, 2015 In people with haemophilia, therapeutic clotting agents might be recognised as a foreign protein and induce anti-factor VIII antibodies, known as 'inhibitors'.
Matino D +4 more
europepmc +2 more sources
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [PDF]
, 2017 The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively.
Franchini, Massimo +6 more
core +1 more source
Factor VII deficiency-related recurrent hemarthrosis in a female child – When to suspect?
Iraqi Journal of Hematology, 2021 Recurrent hemarthrosis is a common entity in children. Although recurrent hemarthrosis most often associated with hemophilia (VIII or IX deficiency), but rarely it can be associated with factor VII deficiency (FVIID).
Siyaram Didel +4 more
doaj +1 more source
Modification of biological parameters after treatment with recombinant factor VIIa in a patient with thrombocytopathy due to storage pool disease [PDF]
, 2005 Patients with thrombocytopathy due to storage pool disease mostly suffer from mild bleeding diathesis. However surgical interventions can lead to excess bleeding.
Almeida +10 more
core +3 more sources
Factor VIIa administration in traumatic brain injury: an AAST-MITC propensity score analysis. [PDF]
, 2018 Background:Recombinant factor VIIa (rFVIIa) has been used off-label as an adjunct in the reversal of warfarin therapy and management of hemorrhage after trauma. Only a handful of these reports are rigorous studies, from which results regarding safety and
Coimbra, Raul +4 more
core +2 more sources
Journal of the Formosan Medical Association, 2006 Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in hemophilic patients with inhibitors. It has also been used to stop bleeding in nonhemophilic patients who fail to respond to conventional treatment.
Yu-Feng Wei +4 more
doaj +1 more source
C2238/αANP modulates apolipoprotein E through Egr-1/miR199a in vascular smooth muscle cells in vitro [PDF]
, 2015 Subjects carrying the T2238C ANP gene variant have a higher risk to suffer a stroke or myocardial infarction. The mechanisms through which T2238C/αANP exerts detrimental vascular effects need to be fully clarified.
Bianchi, Franca +9 more
core +1 more source
Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) – advancing the journey [PDF]
, 2016 The novel fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) is designed to extend the half-life of recombinant factor VIIa (rFVIIa) and improve the care of hemophilia A or B patients with inhibitors.
Legrand, Michel R +2 more
core +1 more source
Low-dose recombinant factor VIIa for massive bleeding
Swiss Medical Weekly, 2011 QUESTIONS UNDER STUDY: recombinant activated factor VII (rFVIIa) is used off-label for massive bleeding. There is no convincing evidence of the benefits of this practice and the minimal effective dose is unknown.
A Mordasini +6 more
doaj +1 more source
Combination of novoseven and feiba in hemophiliac patients with inhibitors
Open Medicine, 2018 The aim of this study is to investigate the effective therapeutic combination of recombinant VIIa(Novoseven) and factor eight inhibitor bypass activity(FEIBA) drugs for the bleedings of adult hemophiliac patients with inhibitors.19 bleeding episodes of 5
Malkan Umit Yavuz, Aksu Salih
doaj +1 more source